Staar Surgical Co. Aktie
Staar Surgical Co. Aktie
Was spricht für und gegen Staar Surgical Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Staar Surgical Co. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | 1,41 % | -1,92 % | -9,78 % | -28,95 % | 31,86 % | -67,50 % | - |
Orasure Tech | 0,94 % | -4,87 % | -12,60 % | -15,69 % | -42,28 % | -42,97 % | -41,16 % |
scPharmaceuticals | 1,09 % | 12,80 % | -10,63 % | -62,81 % | -35,65 % | -19,21 % | - |
SI-BONE Inc | - | 0,82 % | -7,52 % | -46,52 % | -35,26 % | -50,80 % | - |
Kommentare
News
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today